Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 2
2009 2
2010 2
2019 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet.
Sanz MA, Fenaux P, Tallman MS, Estey EH, Löwenberg B, Naoe T, Lengfelder E, Döhner H, Burnett AK, Chen SJ, Mathews V, Iland H, Rego E, Kantarjian H, Adès L, Avvisati G, Montesinos P, Platzbecker U, Ravandi F, Russell NH, Lo-Coco F. Sanz MA, et al. Blood. 2019 Apr 11;133(15):1630-1643. doi: 10.1182/blood-2019-01-894980. Epub 2019 Feb 25. Blood. 2019. PMID: 30803991 Free PMC article. Review.
Together with providing current indications on genetic diagnosis, modern risk-adapted frontline therapy, and salvage treatment, the review contains specific recommendations for the identification and management of the most important complications such as the bleeding disor …
Together with providing current indications on genetic diagnosis, modern risk-adapted frontline therapy, and salvage treatment, the r …
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.
Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, Naoe T, Lengfelder E, Büchner T, Döhner H, Burnett AK, Lo-Coco F. Sanz MA, et al. Blood. 2009 Feb 26;113(9):1875-91. doi: 10.1182/blood-2008-04-150250. Epub 2008 Sep 23. Blood. 2009. PMID: 18812465 Free article. Review.
The introduction of all-trans retinoic acid (ATRA) and, more recently, arsenic trioxide (ATO) into the therapy of acute promyelocytic leukemia (APL) has revolutionized the management and outcome of this disease. ...The European LeukemiaNet recently appointed an inte …
The introduction of all-trans retinoic acid (ATRA) and, more recently, arsenic trioxide (ATO) into the therapy of acute promyelocytic …
Treatment of patients with acute promyelocytic leukemia: a consensus statement on risk-adapted approaches to therapy.
Tallman M, Douer D, Gore S, Powell BL, Ravandi F, Rowe J, Ranganathan A, Sanz MA. Tallman M, et al. Clin Lymphoma Myeloma Leuk. 2010 Oct;10 Suppl 3:S122-6. doi: 10.3816/CLML.2010.s.023. Clin Lymphoma Myeloma Leuk. 2010. PMID: 21115429
In addition, arsenic trioxide has proven efficacy in relapse and when combined with ATRA in frontline regimens has demonstrated high efficacy in a number of trials and the potential to replace chemotherapy, which would thereby reduce chemotherapy-related adverse events. Cure in …
In addition, arsenic trioxide has proven efficacy in relapse and when combined with ATRA in frontline regimens has demonstrated high efficac …
Arsenic trioxide: safety issues and their management.
Au WY, Kwong YL. Au WY, et al. Acta Pharmacol Sin. 2008 Mar;29(3):296-304. doi: 10.1111/j.1745-7254.2008.00771.x. Acta Pharmacol Sin. 2008. PMID: 18298894 Review.
Arsenic trioxide (As2O3) has been used medicinally for thousands of years. Its therapeutic use in leukaemia was described a century ago. Recent rekindling in the interest of As2O3 is due to its high efficacy in acute promyelocytic leukaemia (APL). ...The condition i …
Arsenic trioxide (As2O3) has been used medicinally for thousands of years. Its therapeutic use in leukaemia was described a century a …
ATRA treatment slowed P-selectin-mediated rolling of flowing HL60 cells in a mechano-chemical-dependent manner.
Dong X, Peng S, Ling Y, Huang B, Tu W, Sun X, Li Q, Fang Y, Wu J. Dong X, et al. Front Immunol. 2023 Apr 24;14:1148543. doi: 10.3389/fimmu.2023.1148543. eCollection 2023. Front Immunol. 2023. PMID: 37168856 Free PMC article.
All-trans retinoic acid (ATRA)-induced differentiation of acute promyelocytic leukemia (APL) toward granulocytes may trigger APL differentiation syndrome (DS), but there is less knowledge about the mechano-chemical regulation mechanism of APL …
All-trans retinoic acid (ATRA)-induced differentiation of acute promyelocytic leukemia (APL) toward granulocytes may trigger …
Treatment of acute promyelocytic leukemia by retinoids.
Fenaux P, Wang ZZ, Degos L. Fenaux P, et al. Curr Top Microbiol Immunol. 2007;313:101-28. doi: 10.1007/978-3-540-34594-7_7. Curr Top Microbiol Immunol. 2007. PMID: 17217041 Review.
We review the role of all-trans retinoic acid (ATRA) in the treatment of acute promyelocytic leukemia (APL). The combination of ATRA and conventional anthracycline-ARA-C chemotherapy (CT) has clearly demonstrated its superiority over CT alone (in terms of relapse and survi …
We review the role of all-trans retinoic acid (ATRA) in the treatment of acute promyelocytic leukemia (APL). The combination of ATRA …
Arsenic trioxide as first-line treatment for acute promyelocytic leukemia.
Leu L, Mohassel L. Leu L, et al. Am J Health Syst Pharm. 2009 Nov 1;66(21):1913-8. doi: 10.2146/ajhp080342. Am J Health Syst Pharm. 2009. PMID: 19850784
Toxicities associated with arsenic trioxide include leukocytosis, Q-T interval prolongation, APL differentiation syndrome, and hepatotoxicity. Since 2000, arsenic trioxide has been used as the standard of care for relapsed APL, with remission ra …
Toxicities associated with arsenic trioxide include leukocytosis, Q-T interval prolongation, APL differentiation syndrome …
The expression of p38, ERK1 and Bax proteins has increased during the treatment of newly diagnosed acute promyelocytic leukemia with arsenic trioxide.
Mandegary A, Hosseini R, Ghaffari SH, Alimoghaddam K, Rostami S, Ghavamzadeh A, Ghahremani MH. Mandegary A, et al. Ann Oncol. 2010 Sep;21(9):1884-1890. doi: 10.1093/annonc/mdq034. Epub 2010 Feb 17. Ann Oncol. 2010. PMID: 20164150 Free article.
PATIENTS AND METHODS: Newly diagnosed APL patients were involved and received ATO (0.15 mg.kg/day) for 28 days as induction followed by consolidation therapy. ...RESULTS: Complete remission was observed in 17 (85%) patients with the median duration of 28 days (18-38 …
PATIENTS AND METHODS: Newly diagnosed APL patients were involved and received ATO (0.15 mg.kg/day) for 28 days as induction followed …